Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.79
WX's Cash to Debt is ranked higher than
70% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. WX: 2.79 )
WX' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: 2.79

Equity to Asset 0.72
WX's Equity to Asset is ranked higher than
80% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. WX: 0.72 )
WX' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.8
Current: 0.72

-0.32
0.8
Interest Coverage 53.89
WX's Interest Coverage is ranked higher than
66% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. WX: 53.89 )
WX' s 10-Year Interest Coverage Range
Min: 6.71   Max: 9999.99
Current: 53.89

6.71
9999.99
F-Score: 5
Z-Score: 6.78
M-Score: -2.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.94
WX's Operating margin (%) is ranked higher than
94% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. WX: 16.94 )
WX' s 10-Year Operating margin (%) Range
Min: -8.26   Max: 25.87
Current: 16.94

-8.26
25.87
Net-margin (%) 17.48
WX's Net-margin (%) is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. WX: 17.48 )
WX' s 10-Year Net-margin (%) Range
Min: -25.33   Max: 27.18
Current: 17.48

-25.33
27.18
ROE (%) 15.65
WX's ROE (%) is ranked higher than
90% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. WX: 15.65 )
WX' s 10-Year ROE (%) Range
Min: -26.63   Max: 226.96
Current: 15.65

-26.63
226.96
ROA (%) 11.77
WX's ROA (%) is ranked higher than
94% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. WX: 11.77 )
WX' s 10-Year ROA (%) Range
Min: -18.88   Max: 72.95
Current: 11.77

-18.88
72.95
ROC (Joel Greenblatt) (%) 30.05
WX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. WX: 30.05 )
WX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17.71   Max: 73.69
Current: 30.05

-17.71
73.69
Revenue Growth (3Y)(%) 21.20
WX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. WX: 21.20 )
WX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 10.8   Max: 159.6
Current: 21.2

10.8
159.6
EBITDA Growth (3Y)(%) 13.20
WX's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. WX: 13.20 )
WX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 102.7
Current: 13.2

0
102.7
EPS Growth (3Y)(%) 8.80
WX's EPS Growth (3Y)(%) is ranked higher than
81% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. WX: 8.80 )
WX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 45
Current: 8.8

0
45
» WX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

WX Guru Trades in Q4 2013

Ron Baron 167,200 sh (+883.53%)
Jim Simons 151,000 sh (+58.78%)
Sarah Ketterer 138,400 sh (+29.83%)
Steven Cohen Sold Out
Julian Robertson Sold Out
Columbia Wanger 2,983,877 sh (-0.62%)
Mario Gabelli 65,200 sh (-24.71%)
John Hussman 10,000 sh (-50%)
» More
Q1 2014

WX Guru Trades in Q1 2014

Ron Baron 210,500 sh (+25.9%)
Sarah Ketterer 157,500 sh (+13.8%)
Columbia Wanger 3,334,900 sh (+11.76%)
John Hussman Sold Out
Mario Gabelli 59,700 sh (-8.44%)
Jim Simons 112,801 sh (-25.3%)
» More
Q2 2014

WX Guru Trades in Q2 2014

Jim Simons 127,500 sh (+13.03%)
Columbia Wanger 3,361,141 sh (+0.79%)
Mario Gabelli 57,200 sh (-4.19%)
Ron Baron 201,500 sh (-4.28%)
Sarah Ketterer 126,000 sh (-20%)
» More
Q3 2014

WX Guru Trades in Q3 2014

Jim Simons 235,300 sh (+84.55%)
Sarah Ketterer 180,700 sh (+43.41%)
Ron Baron 201,500 sh (unchged)
Mario Gabelli 57,200 sh (unchged)
Columbia Wanger 3,348,020 sh (-0.39%)
» More
» Details

Insider Trades

Latest Guru Trades with WX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-03-31 Sold Out 0.03%$32.58 - $39.86 $ 34.14-7%0
Ron Baron 2014-03-31 Add 25.9%0.01%$32.58 - $39.86 $ 34.14-7%210500
Julian Robertson 2013-12-31 Sold Out 2.4%$26.52 - $38 $ 34.148%0
Ron Baron 2013-12-31 Add 883.53%0.02%$26.52 - $38 $ 34.148%167200
John Hussman 2013-12-31 Reduce -50%0.02%$26.52 - $38 $ 34.148%10000
Mario Gabelli 2013-12-31 Reduce -24.71%$26.52 - $38 $ 34.148%65200
Julian Robertson 2013-09-30 Reduce -35.37%0.85%$20.23 - $28.48 $ 34.1444%576218
John Hussman 2013-09-30 Reduce -50%0.02%$20.23 - $28.48 $ 34.1444%20000
Ron Baron 2013-09-30 Add 54.55%$20.23 - $28.48 $ 34.1444%17000
Mario Gabelli 2013-09-30 Reduce -26.05%$20.23 - $28.48 $ 34.1444%86600
Julian Robertson 2013-06-30 Reduce -13.99%0.34%$16.94 - $21.54 $ 34.1475%891618
Ron Baron 2013-06-30 New Buy$16.94 - $21.54 $ 34.1475%11000
John Hussman 2013-03-31 New Buy0.03%$15.44 - $17.91 $ 34.14106%40000
Julian Robertson 2012-06-30 Add 6.51%0.28%$13.37 - $14.84 $ 34.14140%1154418
Julian Robertson 2012-03-31 Reduce -24.88%1.67%$11.43 - $15.39 $ 34.14168%1083818
Mario Gabelli 2011-12-31 Reduce -28.82%0.01%$10.78 - $13.92 $ 34.14187%250200
Julian Robertson 2011-09-30 Add 38.6%1.9%$11.56 - $17.26 $ 34.14141%1442806
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on WuXi PharmaTech (Cayman) Inc

Baron Funds Comments on WuXi PharmaTech - Feb 24, 2014

Shares of WuXi PharmaTech (Cayman) Inc. (WX) were strong in the fourth quarter. As the largest Chinese Contract Research Organization (CRO), with an estimated 27% market share, WuXi is a beneficiary of increased pharma outsourcing activity to countries like China and India. Performance during the fourth quarter is attributable to above consensus financial results and a growing pipeline of contract research and manufacturing activity. We retain conviction in the company due to its high growth potential and strong relationships with leading pharmaceutical companies. (Anuj Aggarwal)

From Ron Baron (Trades, Portfolio)'s Baron Funds' fourth quarter 2013 commentary.

Check out Ron Baron latest stock trades

Top Ranked Articles about WuXi PharmaTech (Cayman) Inc

Baron Funds Comments on WuXi PharmaTech
Shares of WuXi PharmaTech (Cayman) Inc. (WX) were strong in the fourth quarter. As the largest Chinese Contract Research Organization (CRO), with an estimated 27% market share, WuXi is a beneficiary of increased pharma outsourcing activity to countries like China and India. Performance during the fourth quarter is attributable to above consensus financial results and a growing pipeline of contract research and manufacturing activity. We retain conviction in the company due to its high growth potential and strong relationships with leading pharmaceutical companies. (Anuj Aggarwal) Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 22.20
WX's P/E(ttm) is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 22.20 )
WX' s 10-Year P/E(ttm) Range
Min: 6.67   Max: 103.94
Current: 22.2

6.67
103.94
P/B 3.20
WX's P/B is ranked higher than
76% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. WX: 3.20 )
WX' s 10-Year P/B Range
Min: 1.11   Max: 10.64
Current: 3.2

1.11
10.64
P/S 3.90
WX's P/S is ranked higher than
71% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. WX: 3.90 )
WX' s 10-Year P/S Range
Min: 0.79   Max: 11.05
Current: 3.9

0.79
11.05
PFCF 21.20
WX's PFCF is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 21.20 )
WX' s 10-Year PFCF Range
Min: 10.85   Max: 141.12
Current: 21.2

10.85
141.12
EV-to-EBIT 19.77
WX's EV-to-EBIT is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 19.77 )
WX' s 10-Year EV-to-EBIT Range
Min: -107.1   Max: 146.9
Current: 19.77

-107.1
146.9
PEG 1.15
WX's PEG is ranked higher than
96% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 1.15 )
WX' s 10-Year PEG Range
Min: 3.95   Max: 4.8
Current: 1.15

3.95
4.8
Shiller P/E 29.10
WX's Shiller P/E is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 29.10 )
WX' s 10-Year Shiller P/E Range
Min: 18.48   Max: 64.93
Current: 29.1

18.48
64.93
Current Ratio 2.37
WX's Current Ratio is ranked higher than
69% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. WX: 2.37 )
WX' s 10-Year Current Ratio Range
Min: 0.79   Max: 5.75
Current: 2.37

0.79
5.75
Quick Ratio 2.20
WX's Quick Ratio is ranked higher than
72% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. WX: 2.20 )
WX' s 10-Year Quick Ratio Range
Min: 0.6   Max: 5.45
Current: 2.2

0.6
5.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.45
WX's Price/Net Cash is ranked higher than
85% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 28.45 )
WX' s 10-Year Price/Net Cash Range
Min: 11.88   Max: 28.57
Current: 28.45

11.88
28.57
Price/Net Current Asset Value 10.77
WX's Price/Net Current Asset Value is ranked higher than
86% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 10.77 )
WX' s 10-Year Price/Net Current Asset Value Range
Min: 5.91   Max: 1193
Current: 10.77

5.91
1193
Price/Tangible Book 3.56
WX's Price/Tangible Book is ranked higher than
83% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. WX: 3.56 )
WX' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 9.09
Current: 3.56

1.45
9.09
Price/DCF (Projected) 2.02
WX's Price/DCF (Projected) is ranked higher than
88% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 2.02 )
WX' s 10-Year Price/DCF (Projected) Range
Min: 1.14   Max: 2.34
Current: 2.02

1.14
2.34
Price/Median PS Value 1.22
WX's Price/Median PS Value is ranked higher than
72% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. WX: 1.22 )
WX' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.85
Current: 1.22

0.3
2.85
Price/Peter Lynch Fair Value 4.31
WX's Price/Peter Lynch Fair Value is ranked higher than
90% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 4.31 )
WX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.25   Max: 4.65
Current: 4.31

0.25
4.65
Price/Graham Number 1.83
WX's Price/Graham Number is ranked higher than
93% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WX: 1.83 )
WX' s 10-Year Price/Graham Number Range
Min: 0.86   Max: 4.93
Current: 1.83

0.86
4.93
Earnings Yield (Greenblatt) 5.20
WX's Earnings Yield (Greenblatt) is ranked higher than
87% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. WX: 5.20 )
WX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 11.9
Current: 5.2

0.7
11.9
Forward Rate of Return (Yacktman) 7.48
WX's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. WX: 7.48 )
WX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.2   Max: 7.7
Current: 7.48

0.2
7.7

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:3W11.Germany,
WuXi PharmaTech (Cayman), Inc. was incorporated on March 16, 2007 and commenced operations and began offering pharmaceutical and biotechnology R&D outsourcing services in 2001. The Company is a pharmaceutical, biotechnology and medical device R&D services company, with operations in China and the United States. It provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers, which includes premier pharmaceutical, biotechnology and medical device companies. Its services are designed to assist its customers in shortening the cycle and lowering the cost of pharmaceutical and medical device R&D by providing cost-effective and efficient outsourcing solutions. Its primary China-based facilities include 1,127,000 square feet of facilities in the China (Shanghai) Pilot Free Trade Zone used for synthetic chemistry, biology, medicinal chemistry, DMPK, formulation, analytical development, manufacturing process chemistry, research manufacturing, bioanalytical services, genomics, and biologics drug discovery and development; an R&D center in Tianjin engaged in synthetic chemistry and medicinal chemistry; a facility in Wuhan providing services in synthetic chemistry and medicinal chemistry; a small-scale cGMP clinical manufacturing facility and a large-scale cGMP commercial manufacturing plant in the Jinshan district of Shanghai; a large-scale non-GMP manufacturing plant in Changzhou; a preclinical toxicology facility in Suzhou; a laboratory for manufacturing research reagents in Suzhou; and a biologics manufacturing facility in Wuxi. It also offers services in biologics and medical device testing in three FDA-registered facilities in the United States. The Company has two segments: Laboratory services and Manufacturing services. Laboratory services are provided for pharmaceutical, biotechnology and medical device companies. China-based laboratory services for pharmaceutical and biotechnology companies include services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical services, genomics, research reagent production, and clinical services, as well as services for discovery and development of biologics. U.S.-based laboratory services include testing services for biologics, medical devices, and combination products. Manufacturing services include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients, or APIs, for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologics. The Company offers testing and development services to ensure that a medical device is manufactured, packaged and sterilized in accordance with GMP guidelines. Its in vivo and in vitro toxicology testing includes bioco
» More Articles for WX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on WuXi PharmaTech Feb 24 2014 
Columbia Management's Top 5 New Buys Amid Buoyant Outlook Aug 12 2013 
comment on WX Sep 15 2012 
Stocks That Are Cheaper Than Julian Robertson Bought Jan 06 2012 
Stocks That Julian Robertson Keeps Buying Dec 23 2011 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Tiger Management Buys WX, CVC, THRX, Sells Apple Inc., Google Inc., Ebay Inc. Nov 15 2010 
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services Dec 09 2008 

More From Other Websites
WuXi Opening Offices in Boston and San Francisco Dec 15 2014
WuXi Opening Offices in Boston and San Francisco Dec 15 2014
WuXi PharmaTech Presents 2014 Life Science and Chemistry Awards Dec 08 2014
WuXi PharmaTech Presents 2014 Life Science and Chemistry Awards Dec 08 2014
WuXi AppTec Wins SCRIP Award for "Best Company in an Emerging Market" Dec 04 2014
WuXi AppTec Wins SCRIP Award for "Best Company in an Emerging Market" Dec 04 2014
WuXi PharmaTech Subsidiary Submits Application to the National Equities Exchange and Quotations in... Dec 03 2014
Another record setting day again on Wall Street Nov 21 2014
Wuxi Pharmatech Cayman Inc Earnings Call scheduled for 8:00 am ET today Nov 13 2014
WuXi PharmaTech Announces Third-Quarter 2014 Results Nov 12 2014
WuXi PharmaTech Announces Third-Quarter 2014 Results Nov 12 2014
WuXi AppTec Announces Enhanced Genomics Services for Chinese Researchers Nov 12 2014
WuXi AppTec Announces Enhanced Genomics Services for Chinese Researchers Nov 12 2014
Q3 2014 WuXi Pharmatech (Cayman) Inc Earnings Release - After Market Close Nov 12 2014
WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2014 Annual General Meeting Nov 11 2014
WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2014 Annual General Meeting Nov 11 2014
WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax Oct 30 2014
WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax Oct 30 2014
WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S.... Oct 23 2014
WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S.... Oct 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK